SCN5A and long QT syndrome 3: We first tested the efficacy of the novel SGK1-I1 on a MEX-sensitive SCN5A-P1332L iPSC-CM derived from a patient with LQT3 and its CRISPR/Cas9 SCN5A-P1332L variant–corrected IC iPSC-CM line.